bicalutamide (Casodex)

approved for treatment of advanced prostate cancer

Also Known As:

Casodex; Cosudex; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide; ICI 176334; ICI-176334; Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-

Networked: 789 relevant articles (79 outcomes, 197 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Iversen, Peter: 14 articles (07/2015 - 08/2002)
2.	Festuccia, Claudio: 10 articles (12/2011 - 09/2002)
3.	Gravina, Giovanni Luca: 10 articles (12/2011 - 09/2002)
4.	See, William A: 10 articles (04/2010 - 08/2002)
5.	McLeod, David G: 8 articles (04/2010 - 08/2002)
6.	Wirth, Manfred P: 8 articles (04/2010 - 08/2002)
7.	Bologna, Mauro: 8 articles (08/2009 - 09/2002)
8.	Vicentini, Carlo: 8 articles (08/2009 - 09/2002)
9.	Wirth, M: 8 articles (01/2007 - 01/2001)
10.	Tammela, Teuvo L J: 7 articles (07/2015 - 08/2002)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 11/01/2021 - "UHRF1 silencing significantly promoted the cytotoxicity and anti-prostate cancer efficacy of bicalutamide in mouse xenografts by inhibiting CDC6 gene expression. " 12/01/1998 - "This clinical trial of bicalutamide confirms the prediction from preclinical studies that a 50 mg dose of bicalutamide would be appropriate for use in patients with advanced prostate cancer, and demonstrates that this bicalutamide dose is clinically effective when administered as part of CAB." 06/01/2012 - "On different prostate cancer cell lines MEL-3 displayed an improved therapeutic profile compared with bicalutamide. " 01/01/1989 - "Following promising results in animal studies, Casodex (ICI 176,334) has been studied in the treatment of patients with advanced prostate cancer. " 04/01/2005 - "Compared to bicalutamide, YM-175735 is an approximately 4-fold stronger AR antagonist and has slightly increased antiandrogenic activity, suggesting that YM-175735 may be useful in the treatment of prostate cancer."
2.	Neoplasms (Cancer) 01/01/2023 - "In this study, bicalutamide resistance genes and hub genes were identified in PCa, a risk model for predicting the prognosis of patients with PCa was constructed, and the tumor mutation heterogeneity and immune infiltration in high- and low-risk groups were analyzed. " 08/01/2010 - "Furthermore, xenograft studies revealed that the combined treatment of 5-Aza with AR-antagonist Bicalutamide had additive/synergistic effects in repressing tumor growth in vivo and the underlying mechanisms responsible for these effects seem to be in part mediated by induction of apoptosis. " 09/01/2023 - "While in BaP group PCa adenocarninoma was the most representative neoplasm, rats treated with 85 and 170 mg/kg prevented it in the light of the casodex. " 05/01/2022 - "The fourth patient had to be managed with oral bicalutamide which kept the tumor stable for 3 years. " 10/01/2021 - "KGN decreased AR nuclear localization and PSA expression, but did not enhance the anti-tumor effect of bicalutamide in LNCaP cells. "
3.	Mastodynia 04/01/2010 - "The overall tolerability of bicalutamide was consistent with previous analyses, with breast pain (73.7%) and gynaecomastia (68.8%) the most frequently reported adverse events in patients randomized to bicalutamide. " 05/01/2005 - "Gynaecomastia and breast pain are frequent adverse events with bicalutamide monotherapy, and might cause some patients to withdraw from treatment. " 06/01/2003 - "The adverse effects most frequently reported in the bicalutamide group were gynaecomastia and breast pain. " 12/01/2002 - "Although better tolerated, bicalutamide has significant problems with gynaecomastia and breast pain. " 01/01/2001 - "Side effects of bicalutamide were mostly gynaecomastia and breast pain, which is consistent with its pharmacology. "
4.	Gynecomastia 08/01/2012 - "We undertook a meta-analysis to assess the efficacy of various treatment options for bicalutamide-induced gynecomastia. " 08/01/2012 - "The medline, cancerlit, and Cochrane library databases were searched and the Google search engine was used to identify prospective and retrospective controlled studies published in English from January 2000 to December 2010 comparing prophylactic or curative treatment options with a control group (no treatment) for pca patients who developed bicalutamide-induced gynecomastia. " 08/01/2010 - "Although prophylactic breast irradiation seemed to decrease the gynecomastia rate in patients on 150 mg bicalutamide, our study proves that not all patients need prophylaxis since only 52% were significantly bothered by gynecomastia. " 04/29/2020 - "Findings of Gynecomastia That Developed in Follow-up Secondary to Bicalutamide Treatment on Bone Scan." 01/01/2017 - "Gynecomastia was recorded in 69.7% of the patients in the bicalutamide group, as compared with 10.9% of those in the placebo group (P<0.001). "
5.	Carcinoma (Carcinomatosis) 09/01/2007 - "Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal." 09/01/2002 - "Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures." 01/01/1996 - "Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial." 12/01/1995 - "Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy." 03/01/1991 - "[Monitoring of erection function in patients with prostatic carcinoma treated with Casodex]."

Related Drugs and Biologics

1.	Androgens
2.	Flutamide (Eulexin)
3.	Gonadotropin-Releasing Hormone (GnRH)
4.	Goserelin (Zoladex)
5.	enzalutamide
6.	Androgen Antagonists (Antiandrogens)
7.	Hormones (Hormone)
8.	Tamoxifen
9.	acetyl- 2- naphthylalanyl- 3- chlorophenylalanyl- 1- oxohexadecyl- seryl- 4- aminophenylalanyl(hydroorotyl)- 4- aminophenylalanyl(carbamoyl)- leucyl- ILys- prolyl- alaninamide
10.	bicalutamide (Casodex)

Related Therapies and Procedures

1.	Therapeutics
2.	Castration
3.	Radiotherapy
4.	Time-to-Treatment
5.	Prostatectomy (Retropubic Prostatectomy)